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Abstract
Background: To evaluate the incidence of chest wall toxicity after lung stereotactic ablative radiotherapy (SABR)
and identify risk factors for the development of rib fracture.
Methods: Thirty-nine patients with 49 lesions underwent SABR for primary or metastatic lung tumors using Cyberknife®
with tumor tracking systems. Patient characteristics, treatment factors and variables obtained from dose-volume
histograms (DVHs) were analyzed to find the association with chest wall toxicity. Four-dimensional (4D) dose
calculations were done to investigate the effect of respiratory motion on dose to the ribs.
Results: After follow-up of median 26.7 months (range: 8.4 – 80.0), 8 patients (20.5%) experienced rib fractures and
among these patients, three (37.5%) had chest wall pain at 2–3 months after SABR. Median time to rib fracture was 13.
4 months (range: 8.0 – 38.5) and the 2-year actuarial risk of rib fracture was 12.2%. Dose to the 4.6 cc of the ribs (D4.6cc)
and rib volume received 160 Gy or more (V160) were significant predictor for rib fracture. No significant differences
between three-dimensional (3D) and 4D dose calculations were found.
Conclusions: Parameters from DVH are useful in predicting the risk of chest wall toxicity after SABR for lung tumors.
Efforts should be made to reduce the risk of the rib fracture after lung SABR.
Keywords: Stereotactic ablative radiotherapy, Lung tumor, Chest wall toxicity, Rib fracture, Dose-volume histogram, 4D
dose calculation
Background
Excellent local control rates have been reported in
stereotactic ablative body radiotherapy (SABR) for early
stage lung cancer [1–3]. Based on the promising treat-
ment outcome equivalent to surgery, SABR is considered
as an alternative treatment not only in medically inoper-
able patients, but also in operable patients [4–6]. Higher
dose to the tumor improves local control rate, but at the
same time, it also increase the dose to the adjacent nor-
mal tissues. In general, SABR is well tolerated and the
reported incidences of acute and late toxicities are low.
However, use of large dose per fraction and increased
survival of patients raised concerns about late toxicities
different from conventional radiotherapy. Several studies
reported the chest wall toxicity such as radiation in-
duced rib fracture (RIRF) or chest wall pain as late toxic-
ities of SABR. The reported incidences of chest wall
toxicity in SABR are generally higher than those in con-
ventional radiotherapy and vary widely among studies
[7]. Chest wall or rib is considered as an important
organ at risk in lung SABR, but consensus on dose con-
straint for these has not been reached [8–10].
Cyberknife® is an image-guided radiotherapy system
with linear accelerator mounted on a robotic arm [11]. It
provides a real-time tumor tracking system which cor-
rects for respiratory motions by moving robotic arm
[12]. Therefore, using tumor tracking systems, it is ex-
pected to provide more accurate targeting of tumors and
lower radiation dose to adjacent normal tissues. Previous
studies demonstrated the efficacy of SABR using Cyber-
knife® and real-time tumor tracking in early stage lung
cancer [13–15]. A recent study by Roth et al. reported
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that dosimetric and radiobiologic indices were compar-
able between Cyberknife® and LINAC-based SABR, how-
ever, the comparability was not verified in terms of
clinical outcome or toxicity [16].
The purpose of this study is to report the incidence of
chest wall complication in patients with primary or meta-
static lung tumors treated with SABR using real-time
tumor tracking and to identify adequate dose constraints
for ribs by evaluating the dose-volume parameters.
Methods
Patients
We retrospectively evaluated total 44 patients who were
treated with SABR for primary or metastatic lung tumors
from July 2008 to October 2014 at Soonchunhyang Uni-
versity Seoul Hospital. Patients with follow-up duration
less than 6 months were excluded in this study. Multiple
lesions were considered as separate if their dose distribu-
tions were minimally overlapped (no overlapped ribs be-
tween isodose lines of 10 Gy in 2 Gy equivalent dose,
EQD2). In case of re-irradiation or adjacent lesions of pre-
vious radiotherapy, the lesions were regarded as one lesion
and dose distributions of each plan were summated on
fused computed tomography (CT) images. Final 39 pa-
tients with 49 lesions were analyzed. Ten patients with 20
lesions received multiple course of thoracic radiotherapy
including both conventional radiotherapy and/or SABR.
Four patients with 11 lesions received different course of
SABR to separate lesions in which their dose distribu-
tions were not overlapped to each other. One patient
received SABR to the recurrent lesion of previous
SABR and one to the recurrent lesion of previous con-
ventional radiotherapy. Two patients had two adjacent
lesions all treated with SABR so those lesions were con-
sidered as one, and summated dose distributions were
analyzed for dosimetric evaluations.
Radiotherapy
All patients were treated with Cyberknife® (Accuray, Inc.,
Sunnyvale, CA, USA) and immobilized with Vac-Lok®
(MEDTEC, Orange City, IA, USA) in supine position.
Treatments were delivered with real-time tumor tracking
using X-sight® Lung (Accuray, Inc., Sunnyvale, CA, USA)
or fiducial-based target tracking (Synchrony® (Accuray,
Inc., Sunnyvale, CA, USA). A fiducial marker was inserted
at the center of tumor in 35 lesions (71.4%). Gross tumor
volume (GTV) was contoured on lung window setting
and planning target volume (PTV) was generated by add-
ing 3–5 mm margin to the GTV. Total dose of 45–66 Gy
was prescribed to the 80% isodose line in 3 to 6 fractions
depending on the risks of surrounding normal organs.
Dose to the ribs were not constrained on the original
treatment plans.
Clinical evaluation
All the medical records of included patients were retro-
spectively reviewed and any symptoms related to chest
wall complication were assessed. Follow-up CTs on the
bone window setting were reviewed to detect the rib
fracture and the time interval between the first day of
SABR and initial appearance of rib fracture was mea-
sured. Only newly detected rib fractures within the
SABR field were recorded as RIRF and fractures second-
ary to tumor recurrence or progression were excluded.
Rib fracture and chest wall pains were graded according
to the criteria for “fracture” and “pain” in Common Ter-
minology Criteria for Adverse Events (CTCAE, v4.0).
Chest wall pain existed before SABR with no change
in its intensity after SABR or those not correlated
with the treatment field were not considered as radi-
ation induced toxicity.
Dosimetric evaluations
Because patients were treated with various dose fraction-
ation schedules, we calculated the EQD2 with α/β ratio
of 3 Gy for ribs [17–19]. All ribs receiving EQD2 of
10 Gy or more were contoured on the planning CT and
dose-volume histograms (DVHs) were generated. Based
on the DVH, the maximum point dose of irradiated rib
(Dmax), absolute dose received by rib volumes of V (DV)
and absolute rib volume receiving a threshold dose D
(VD) were calculated.
4D dose calculations
We have used 4-dimensional (4D) CT scanning tech-
nique since 2013 to monitor the tumor motion and to
use for contouring and evaluating the target coverage
with respiration although only 3-dimensional (3D) dose
calculations have been used for all clinical treatment
planning. Dose calculations of these patients were done
using Monte Carlo algorithm. To evaluate the accuracy
of 3D dose calculation for ribs, full sets of 4D CT images
for 9 lesions from 7 patients were successfully reloaded.
The raw data of 4D CT were binned into 10 phases and
ten 3D CT datasets were reconstructed. Each respiratory
phase was registered based on fiducial markers using
MIM software (MIM Software Inc. Cleveland, OH). After
the image registration, the cumulative dose was deter-
mined by combining dose distribution of each phase.
Statistical analysis
All statistical analyses were performed using SPSS ver-
sion 18.0 (SPSS Inc., Chicago, IL). Actuarial rates of rib
fracture, local control and overall survival were calculated
with Kaplan-Meier Methods and the log-rank test was
used to compare the risk factors on univariate analysis.
Cox proportional-hazard model was used for multivariate
analysis. The receiver operating characteristic (ROC)
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curves were generated to assess the optimal cut-off values
of DHV parameters and their predictability of rib frac-
tures. Areas under the curves (AUCs) were calculated to
compare the cut-off values. P-values less than 0.05 were
considered to be statistically significant.
Results
The median follow-up was 26.7 months (range, 8.4 –
80.0 months). The local control rates at 2 years were
88.0%. The patients and tumor characteristics are summa-
rized in Table 1. Median age at SABR was 66 years (range,
46 – 84 years). More than half of the patients (57.1%) had
primary or recurrent lung cancer lesions and 30 lesions
(61.2%) were located in middle or lower lobe. Median
GTV volume was 5.90 cc (range, 0.79 – 111.74 cc) and
median distance between rib and tumor was 0.25 cm
(range, 0.00 – 4.10 cm).
Chest wall toxicity
Rib fractures were identified in 8 patients and actuarial
incidence of rib fracture was 12.2% at 2 years and 16.6%
at 3 years (Fig. 1). Five patients had Grade 1 rib frac-
tures, one had Grade 2 and two had Grade 3. Time
interval from SABR to the rib fracture was median
13.4 months (range, 8.0 – 38.5 months). Three patients
complained of Grade 1 chest wall pain at 2–3 months
after SABR without any evidence of rib fracture at that
time. One patient need non-opioid analgesics and the
other two did not need any analgesics. All these patients
eventually developed Grade 3 rib fractures after longer
follow-up, but the statistically significant associations
were not found between chest wall pain and Grade of
rib fractures. There was no patient who had chest wall
pain alone without rib fractures. Therefore, we analyzed
the risk factor for rib fractures in subsequent analysis.
Dose-volume analysis of rib fracture
From DVHs, Dmax and D0.1cc to D10cc were derived in
0.1 cc increments from 0.1 to 5 cc and 1 cc increments
from 5 cc to 10 cc. Volume of ribs receiving EQD2 of
50 Gy to 300 Gy were also obtained in 10 Gy increments.
The AUCs of each parameter were calculated and the
maximum AUC of DV was at 4.6 cc (p = 0.010) and
VD was at EQD2 of 160 Gy (p = 0.005), and these pa-
rameters were selected as predictors for rib fractures.
Based on the sensitivity and specificity, 140 Gy and
3.2 cc volume of rib were selected as cut-off values
for D4.6cc and V160, respectively.
Clinical and dosimetric risk factors for rib fracture
A representative case of dose distribution and rib frac-
ture on CT image is shown in Fig. 2. The results of uni-
variate and multivariate analysis are summarized in
Table 2. On univariate analysis, no clinical factors
showed significant association with RIRF but rib-tumor
distance, D4.6cc and V160 were significant risk factors
(p = 0.035, p = 0.001 and p = 0.000, respectively). Three
factors, rib-tumor distance, D4.6cc and V160 were signifi-
cantly associated to each other, therefore, to avoid multicol-
linearity, only D4.6cc was included on multivariate analysis.
On multivariate analysis, D4.6cc was confirmed as a signifi-
cant risk factor for RIRF (p = 0.009). Cumulative incidence
of RIRF according to the D4.6cc is shown in Fig. 3.
4D dose calculation
When the DVHs of 3D and 4D dose calculations were
compared, no significant differences in dose to ribs (V160
and D4.6cc, p = 0.368 and p = 0.254, respectively by paired
Table 1 Patients and tumor characteristics
Characteristic Number (% or range)
Age (year) Median 66 (46–84)
Sex Male 23 (59.0)
Female 16 (41.0)




DM Yes 11 (22.4)
No 38 (77.6)
COPD Yes 9 (18.4)
No 40 (81.6)
Tumor location Upper lobe 19 (38.8)
Middle and lower lobe 30 (61.2)
GTV volume (cc) Median 5.90 (0.79 – 111.74)
Rib-tumor distance (cm) Median 0.25 (0.00 – 4.10)
DM diabetes mellitus, COPD chronic obstructive pulmonary disease, GTV gross
tumor volume
Fig. 1 Cumulative incidence of rib fracture after SABR
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t-test) were found (Fig. 4). Tumor location, distance be-
tween rib and tumor, and tumor size did not affect the
differences of two dose calculations. Difference between
two dose calculations did not affect the development of
rib fractures.
Discussion
Overcoming the treatment errors caused by respiratory
motion is a great challenge in radiotherapy for lung tu-
mors. Various techniques have been suggested as solutions
for this problem and real-time tumor tracking is one of
the options [20]. In our study, the cumulative incidence of
RIRF was 12.2 and 16.6% in 2 and 3 years, respectively.
According to the previous studies, the incidence of RIRF
after SABR varies from 20 to 40% [21–24]. Difference of
selection criteria of included patients and different frac-
tionation scheme precludes direct comparison between
studies, however, the incidence of RIRF in our study was
lower than those in previous studies, in general. Recently,
Lischalk et al. reported long-term outcome of non-small
cell lung cancer patients treated with Cyberknife® using fi-
ducial tracking [25]. Although their incidence of rib frac-
ture was higher (21.4% in 2 years) than that in our study,
it was relatively lower than those in most other studies.
Highly conformal dose distribution of Cyberknife® and
real-time tumor tracking system could result in the low
incidence of RIRF. Association between radiation dose to
ribs and risk of rib fractures has been suggested in previ-
ous studies. Various dose-volume parameters such as
Dmax, D0.5cc, D8.0cc and V30 to V70 have been shown to be
significant risk factors for RIRFs [21, 22, 24, 26–28]. In a
pooled analysis of patients undergoing SABR with 2 differ-
ent types of treatment machine (LINAC and Cyberknife®),
10% risk level for grade 2 or higher chest wall complica-
tion for D2cc was 43.0 Gy in 4 fractions [29]. A recent
study by Okoukoni et al. reported early cortical thinning
of ribs after SABR in regions of receiving ≥10 Gy and sug-
gested that rib thinning would contribute to the occur-
rence of rib fractures [30]. In our study, various
parameters were associated with RIRF but D4.6cc and V160
were most predictive. D4.6cc less than EQD2 of 140 Gy, is
equivalent to 41.7 Gy in 3 fractions which is higher than
previously suggested cut-off values, Dmax of 42.4 Gy in 4
fraction [21] or 54 Gy in 7–9 fractions [24] and D8.0cc of
54 Gy in 4 fractions [26].
Fig. 2 Example of radiation induced rib fracture and dose distribution. A 74-year-old man treated for adenocarcinoma in right lower lobe developed
rib fracture after 37 months. The prescribed dose was 66 Gy in 3 fractions. a Dose distribution in the transverse plane corresponding to the site of rib
fracture. Red area represents the isodose line of 160 Gy in EQD2. b Rib fracture detected on follow-up CT (arrow)
Table 2 Univariate and multivariate analysis of risk factors for
radiation induced rib fracture
Rib fracture p-value
Variables No Yes Univariate Multivariate
Sex Male 26 4 0.493 NS
Female 15 4
Age ≤65 18 3 0.636 NS
>65 23 5
Tumor location Upper lobe 15 4 0.086 NS
Lower lobea 26 4
Multiple
treatment
No 24 5 0.759 NS
Yes 17 3
DM No 32 6 0.581 NS
Yes 9 2
COPD No 35 5 0.061 NS
Yes 6 3
GTV volume ≤17 cc 33 4 0.097 NS
>17 cc 8 4
Rib-tumor
distance
≤0.4 cm 21 8 0.035 _
>0.4 cm 20 0
D4.6cc ≤140 Gy,
EQD2




V160 ≤3.2 cc 27 0 0.000 _
>3.2 cc 22 8
aincludes middle lobe in case of right lung
DM diabetes mellitus, COPD chronic obstructive pulmonary disease, GTV gross
tumor volume
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Rib-tumor distance was significantly associated with
rib fractures in previous studies [18, 28]. Asai et al. sug-
gested rib-tumor distance less than 2 cm as a significant
risk factor [21] and Bongers et al. reported more grade 3
chest wall toxicity in tumors within 25 mm from chest
wall [18]. But in our study, most of the lesions were lo-
cated less than 2 cm from ribs (83.7%) and 0.4 cm was
selected as cutoff value. Lesions close to chest wall inev-
itably result in higher dose to larger volume of ribs,
therefore the rib-tumor distance was significantly associ-
ated with D4.6cc and V160 (P < 0.05). Although rib-tumor
distance was excluded in the multivariate analysis to ex-
clude multicollinearity, it is suggested as a good pre-
dictor for RIRF.
Regarding tumor size, median gross tumor volume
was 5.90 cc ranging from 0.79 cc to 111.74 cc, indicating
that our study included larger lesions compared with
other studies [18, 24, 27]. Larger tumor predicts larger
dose to adjacent normal tissues and more toxicity is ex-
pected. Bongers et al. identified the PTV size as a signifi-
cant risk factor for chest wall pain [18] and tumor
dimension and PTV volume were correlated with chest
wall toxicity in study by Stephans et al. [27].
As we have seen above, despite of unfavorable factors,
our result showed low incidence of RIRF. All the pa-
tients in our study were treated with real-time tumor
tracking system. The tumor tracking system has been
shown to improve the treatment accuracy and low tox-
icity of SABR with real-time tumor tracking in lung
cancer patients has been reported, although all these were
single arm studies with no control groups [13, 15, 31].
Therefore, use of real-time tumor tracking in all patients
should have contributed to the low incidence of RIRF.
Of the three patients with chest wall pain, one com-
plained of chest wall pain at 2 months after SABR and
the other two at 3 months after SABR. All these patients
developed rib fractures with longer follow-up. Compat-
ible with our result, reported duration from SABR to
chest wall pain were generally shorter than the duration
to rib fractures [7]. The mechanism of chest wall pain is
thought to be different from that of rib fractures and the
intercostal nerve injury is suggested as a possible cause
of chest wall pain [32]. Because of steep dose gradient,
irradiated volume of chest wall is small in our study and
this might have contributed to the low incidence of
chest wall pain. Although the relationship between chest
wall pain and rib fractures is not identified, our results
suggest the need for close observation of the patients
with chest wall pain.
Because of respiration, lung undergoes continuous
motion and deformation. But in clinical setting, 3D dose
calculations are used for treatment planning for radio-
therapy. This raised concerns about the discrepancies in
planned dose and actually delivered dose to target. Sev-
eral studies investigating this issue found that there were
small difference between 3D and 4D calculations and 3D
dose calculations can provide good approximation of 4D
dose calculations in clinical setting [33–35]. Recent
Fig. 3 Cumulative incidence of radiation induced rib fracture after SABR
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Fig. 4 Comparison of 3D and 4D dose calculations in a representative patient. The male patient was treated for squamous carcinoma of left lower
lung with 60 Gy in 3 fractions. The maximum diameter of tumor was 2.1 cm and the PTV was abutting the rib. After 1 year follow-up, no
rib fracture was found. a DVH of two dose calculations. Solid line: 4D dose calculation, Dashed line: 3D calculation. b Representative transverse plane of
dose distributions. Left: 3D calculation, right: 4D calculation
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study by Chan et al. [36] argued that 4D Monte Carlo
optimization provide more accurate planning than 3D
optimization or 4D dose renormalization. However, accord-
ing to their results, only conformity index was significantly
different and the absolute differences were very small. Due
to the small differences, the tumor control probability did
not changed after 4D dose calculations. Moreover, there
were no significant differences in dose to normal organs
and normal tissue complication probability. It is remark-
able that they showed the actual difference of 3D and 4D
dose calculations but the differences have little impact on
the clinical results and this support the results of our study.
Most of the lesions included in our study were peripheral
lesions with the median rib-tumor distances of 0.25 cm.
Therefore, we expected 4D calculations could provide
more accurate risk estimation for rib fractures, but no sig-
nificant differences were found between 3D and 4D dose
calculations. Tumor characteristics such as rib-tumor dis-
tances and tumor locations did not affect the difference of
two dose calculations. Therefore, our results confirmed the
result of previous studies and 3D dose calculation can be
used to predict the normal tissue toxicity in SABR for lung
tumors. Because of limited number of lesions included in
our study, further studies involving more patients in pro-
spective setting are needed to validate this.
There are several limitations to our study. First, it is
retrospective study and the interval of follow-up evalua-
tions and image work up was not exactly the same in all
the patients. Therefore patient reported outcomes such as
low grade chest wall pain might be underestimated and
the development of asymptomatic rib fractures could be
recorded with a delay. Second, included patients were
treated with various fractionation scheme and some pa-
tients received multiple course of thoracic radiotherapy.
Although, we used linear-quadratic model and calculated
EQD2 and DVH parameters were obtained from sum-
mated dose of multiple treatment plans, this heterogen-
eity of study population might have caused undetected
bias or errors. However, in clinical settings, more di-
verse fractionation schemes are used and more patients
are undergoing multiple course of radiotherapy, inclu-
sion of various fractionation schemes and heteroge-
neous patients could provide more practical guideline.
Conclusions
In conclusion, SABR in primary or metastatic lung tu-
mors using real-time tumor tracking provides excellent
tumor controls with low incidence of chest wall toxicity.
Rib-tumor distance, D4.6cc and V160 are significant risk
factor for RIRF and by limiting dose to the 4.6 cc volume
of rib would prevent RIRF. In clinical setting, 3D dose
calculations can substitute 4D dose calculations for esti-
mation of rib fracture risks. This results need to be vali-
dated in the future studies.
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